Actively Recruiting

FEMALE
NCT05046080

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Led by M.D. Anderson Cancer Center · Updated on 2026-02-19

70

Participants Needed

1

Research Sites

268 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.

CONDITIONS

Official Title

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Who Can Participate

FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with clear cell carcinoma of the cervix at MDACC
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here